Clopidogrel
- Generic Name
- Clopidogrel
- Brand Names
- Duoplavin, Plavix, Zyllt, Clopidogrel BGR (previously Zylagren), Clopidogrel TAD, Clopidogrel ratiopharm, Clopidogrel Zentiva (previously Clopidogrel Winthrop), Clopidogrel Krka, Clopidogrel Krka d.d. (previously Zopya), Clopidogrel Teva (hydrogen sulphate), Clopidogrel HCS, Iscover, Grepid, Clopidogrel Taw Pharma (previously Clopidogrel Mylan), Clopidogrel Viatris (previously Clopidogrel Taw Pharma)
- Drug Type
- Small Molecule
- Chemical Formula
- C16H16ClNO2S
- CAS Number
- 113665-84-2
- Unique Ingredient Identifier
- A74586SNO7
- Background
Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke. Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial diseas...
- Indication
1.用于新近心肌梗死、新近脑卒中或确诊的周围动脉病变患者，可减少新的缺血性脑卒中、心肌梗死和死亡等心脑血管事件的符合终点；
2.用于急性冠状动脉综合征（不稳定心绞痛和非ST段抬高心肌梗死）患者；
3.用于冠状动脉支架置入术后预防支架内血栓形成（与阿司匹林联用）。
- Associated Conditions
- Acute Coronary Syndrome (ACS), Acute Myocardial Infarction (AMI), Cardiovascular Events, Atherothrombotic events
- Associated Therapies
- -
VerifyNow to Optimise Platelet Inhibition in Coronary Acute Syndrome
- Conditions
- Interventions
- First Posted Date
- 2020-12-04
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Fundación EPIC
- Target Recruit Count
- 634
- Registration Number
- NCT04654052
- Locations
- 🇪🇸
Hospital Universitario Virgen de La Arrixaca, El Palmar, Murcia, Spain
🇪🇸Hospital General Universitario de Albacete, Albacete, Spain
🇪🇸Hospital Del Mar, Barcelona, Spain
Safety and Efficacy of Ticagrelor vs Clopidogrel in Patients With Acute Coronary Syndrome
- Conditions
- Interventions
- First Posted Date
- 2020-11-16
- Last Posted Date
- 2020-11-16
- Lead Sponsor
- Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud
- Target Recruit Count
- 1900
- Registration Number
- NCT04630288
- Locations
- 🇪🇸
Hospital Universitario Virgen Macarena, Sevilla, Spain
🇪🇸Fundación Pública Progreso y Salud, Sevilla, Spain
The 3 Years vs 1 Year DAPT After XINSORB BRS Implantation
- First Posted Date
- 2020-08-06
- Last Posted Date
- 2020-08-06
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 2106
- Registration Number
- NCT04501900
Tailoring P2Y12 Inhibiting Therapy in Patients Requiring Oral Anticoagulation After PCI
- Conditions
- Interventions
- First Posted Date
- 2020-07-23
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 80
- Registration Number
- NCT04483583
- Locations
- 🇺🇸
University of Florida, Jacksonville, Florida, United States
Effect of Berberine for Endothelial Function and Intestinal Microflora in Patients With Coronary Artery Disease
- First Posted Date
- 2020-06-16
- Last Posted Date
- 2020-06-16
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 24
- Registration Number
- NCT04434365
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
SMart Angioplasty Research Team: CHoice of Optimal Anti-Thrombotic Strategy in Patients Undergoing Implantation of Coronary Drug-Eluting Stents 3
- First Posted Date
- 2020-06-05
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Joo-Yong Hahn
- Target Recruit Count
- 5506
- Registration Number
- NCT04418479
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Prevention of Arteriovenous Thrombotic Events in Critically-Ill COVID-19 Patients Trial
- First Posted Date
- 2020-06-01
- Last Posted Date
- 2024-01-19
- Lead Sponsor
- The TIMI Study Group
- Target Recruit Count
- 390
- Registration Number
- NCT04409834
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Cilostazol and Endothelial Progenitor Cell
- Conditions
- Interventions
- First Posted Date
- 2020-05-29
- Last Posted Date
- 2020-05-29
- Lead Sponsor
- Gyeongsang National University Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT04407312
Efficacy and Safety of Individualized P2Y12 Receptor Antagonists Treatment Based on Agregometry Versus Fixed Dose Regimen in Patients After Acute Myocardial Infarction
- Conditions
- Interventions
- First Posted Date
- 2020-04-30
- Last Posted Date
- 2020-04-30
- Lead Sponsor
- University of Zagreb
- Target Recruit Count
- 120
- Registration Number
- NCT04369534
- Locations
- 🇭🇷
Uhiversity hospital Center Zagreb, Zagreb, Croatia
Enhanced Platelet Inhibition in Critically Ill Patients With COVID-19
- First Posted Date
- 2020-04-29
- Last Posted Date
- 2020-04-29
- Lead Sponsor
- University of Milan
- Target Recruit Count
- 5
- Registration Number
- NCT04368377
- Locations
- 🇮🇹
L. Sacco Hospital, Milano, Lombardia, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.